- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05242744
FTT PET/CT in Metastatic Prostate Cancer
April 17, 2023 updated by: Abramson Cancer Center at Penn Medicine
Evaluating in Vivo PARP-1 Expression With 18F-FluorThanatrace Positron Emission Tomography (PET/CT) in Patients With Metastatic Prostate Cancer
Up to 30 men with metastatic prostate cancer will undergo up to 2 FTT PET/CT scans to look at PARP activity in sites of known cancer.
Subjects will undergo a baseline scan prior to starting new therapy and a second, optional, post-therapy scan 1-21 days after the start of treatment.
Tissue from a clinical or research biopsy will be compared to imaging measures, if available.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
Up to 30 evaluable patients with a histological diagnosis of prostate cancer with clinical evidence of metastatic disease who are being considered for new therapy or for a change in therapy with a PARP inhibitor, androgen deprivation therapy, and/or chemotherapy as part of their clinical care will be enrolled in this study.
A pre-treatment 18F-FluorThanatrace ([18F]FTT) positron emission tomography/ computed tomography (PET/CT) scan will be done prior to the start of a new therapy regimen.
PET/CT imaging will be used to evaluate PARP-1 expression in sites of prostate cancer using the investigational radiotracer [18F]FTT.
This is an observational study in that [18F]FTT PET/CT will not be used to direct treatment decisions.
While patients and referring physicians will not be blinded to the [18F]FTT PET/CT results, treatment decisions will be made by the treating physicians based upon clinical criteria.
After injection of [18F]FTT patients will undergo a skull base to mid-thigh scan, starting at approximately 60 minutes post injection.
PET/CT imaging sessions will include an injection of 12 mCi of [18F]FTT intravenously (approximate range for most studies is anticipated to be 8-12 mCi ). of [18F] FTT.
Data will be collected to evaluate uptake of [18F]FTT in sites of prostate cancer, which will be compared with PARP-1 expression in tissue, when available.
All evaluable patients may start new therapy following the [18F]FTT PET/CT scan.
It is expected that due to patient preference and time considerations, approximately 80% will also undergo a second (optional) scan that will be performed approximately 1-21 days after new therapy has started.
The second scan is obtained to evaluate whether the initiation of a PARP inhibitor and/or androgen deprivation therapy and/or chemotherapy alters [18F] FTT uptake.
Study Type
Observational
Enrollment (Anticipated)
30
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Erin Schubert, BA
- Phone Number: 215-573-6569
- Email: erin.schubert@pennmedicine.upenn.edu
Study Contact Backup
- Name: Ashley Veronsky, BA
- Phone Number: 215-898-4346
- Email: ashley.veronsky@pennmedicine.upenn.edu
Study Locations
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- Recruiting
- University of Pennsylvania Hospital
-
Contact:
- Erin Schubert
- Phone Number: 2155736569 215-573-6569
- Email: erin.schubert@pennmedicine.upenn.edu
-
Principal Investigator:
- Neil Taunk, MD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
N/A
Sampling Method
Non-Probability Sample
Study Population
Patients with a histological diagnosis of prostate cancer with clinical evidence of metastatic disease who are being considered for new therapy or for a change in therapy with a PARP inhibitor, androgen deprivation therapy, and/or chemotherapy as part of their clinical care.
Description
Inclusion Criteria:
- Participants will be ≥ 18 years of age
- Histologically proven prostate carcinoma
- Clinical evidence of metastatic disease with at least one lesion identified on standard of care imaging (CT, MRI, Bone Scan, FDG or other PET/CT, Ultrasound)
- Considered a candidate for new therapy or change in therapy with PARP inhibitor therapy and/or androgen deprivation therapy (ADT) and/or chemotherapy with or without additional agents, either on a clinical trial or as part of clinical care.
- Participants must be informed of the investigational nature of this study and be willing to provide written informed consent and participate in this study in accordance with institutional and federal guidelines prior to study-specific procedures.
Exclusion Criteria:
- Inability to tolerate imaging procedures in the opinion of an investigator or treating physician
- Any current medical condition, illness, or disorder as assessed by medical record review and/or self-reported that is considered by a physician investigator to be a condition that could compromise participant safety or successful participation in the study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Case-Only
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Metastatic prostate cancer
Men at least 18 years of age with metastatic prostate cancer may be eligible for this study .Volunteers that meet the eligibility criteria will be considered for study participation regardless of race or ethnic background.
Only individuals who can understand and give informed consent will be eligible to participate in this study.
|
Investigational radiopharmaceutical used with Positron Emission Tomography (PET/CT) imaging that may provide a non-invasive measurement of PARP-1 expression
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Measurement of effect size
Time Frame: 21 days
|
To establish effect size of change in FTT uptake before and after systemic therapy in men with prostate cancer metastasis using [18F]FluorThanatrace ([18F]FTT)
|
21 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evaluation of PARP expression
Time Frame: 21 days
|
Evaluation of PARP-1 expression in prostate cancer using measures of uptake of [18F]FTT before and after PARPi and/or androgen deprivation therapy and/or chemotherapy
|
21 days
|
Correlation with PARP-1 IHC
Time Frame: 6 months
|
Correlation of [18F]FTT uptake measures with PARP-1 IHC expression in the tissue specimen, when available
|
6 months
|
Correlation with PARP-1 autoradiography
Time Frame: 6 months
|
Correlation of [18F]FTT uptake measures with PARP-1 [125I]KX1 autoradiography expression in the tissue specimen, when available
|
6 months
|
Predication of clinical response
Time Frame: 1 year
|
Determination of whether baseline and/or pre-/post-treatment changes in [18F]FTT uptake predict clinical response as measured by progression-free survival (PFS) and anatomic criteria on standard of care imaging
|
1 year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Neil Taunk, MD, University of Pennsylvania
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 1, 2023
Primary Completion (Anticipated)
July 1, 2024
Study Completion (Anticipated)
July 1, 2024
Study Registration Dates
First Submitted
February 8, 2022
First Submitted That Met QC Criteria
February 8, 2022
First Posted (Actual)
February 16, 2022
Study Record Updates
Last Update Posted (Actual)
April 18, 2023
Last Update Submitted That Met QC Criteria
April 17, 2023
Last Verified
April 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- UPCC 08821
- 849671 (Other Identifier: Abramson Cancer Center)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Prostate Cancer Metastatic
-
Imperial College LondonWellcome Trust; Imperial Clinical Trials Unit (ICTU)CompletedProstate Cancer | Metastatic Prostate Cancer | Prostate Adenocarcinoma | Prostate Cancer Metastatic | Metastatic Prostate Carcinoma in the Soft Tissue | Non-metastatic Prostate CancerUnited Kingdom
-
The University of Texas Health Science Center at...WithdrawnMetastatic Prostate Cancer | Prostate Cancer Metastatic | Metastatic Prostate Adenocarcinoma | Castrate Resistant Prostate CancerUnited States
-
Dana MathewsWithdrawnProstate Cancer | Prostate Cancer Metastatic | Prostate Cancer Metastatic to BoneUnited States
-
Herlev and Gentofte HospitalBristol-Myers SquibbRecruitingProstate Cancer Metastatic | Metastatic Castration-resistant Prostate Cancer | Castrate Resistant Prostate Cancer | Prostate Cancer Stage IVDenmark
-
Myovant Sciences GmbHRecruitingMetastatic Castration-Resistant Prostate Cancer | Metastatic Castration-Sensitive Prostate Cancer | Non-Metastatic Castration-Resistant Prostate CancerUnited States
-
Bellicum PharmaceuticalsSuspendedMetastatic Prostate Cancer | Metastatic Castration-resistant Prostate CancerUnited States
-
Tavanta TherapeuticsCompletedMetastatic Prostate Cancer | Metastatic Castration-sensitive Prostate Cancer | Metastatic Castration-resistant Prostate CancerUnited States, Spain, United Kingdom, Hungary, France, Poland, Puerto Rico, Sweden
-
Memorial Sloan Kettering Cancer CenterProgenics Pharmaceuticals, Inc.RecruitingProstate Cancer | Metastatic Prostate Cancer | Prostate Adenocarcinoma | Prostate Cancer Metastatic | Prostate NeoplasmUnited States
-
Vadim S KoshkinEli Lilly and Company; Prostate Cancer FoundationActive, not recruitingCastration-Resistant Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8 | Metastatic Castration-resistant Prostate Cancer | Metastatic Prostate Adenocarcinoma | Metastatic Castration-resistant Prostate CarcinomaUnited States
-
WntResearch ABCompletedMetastatic Breast Cancer | Metastatic Prostate Cancer | Metastatic Colon CancerDenmark, United Kingdom
Clinical Trials on [18F]FluorThanatrace
-
Heather WachtelRecruitingPheochromocytoma | ParagangliomaUnited States
-
Abramson Cancer Center at Penn MedicineActive, not recruiting
-
Abramson Cancer Center at Penn MedicineRecruitingSuspected Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal CancerUnited States
-
Washington University School of MedicineActive, not recruiting
-
Abramson Cancer Center at Penn MedicineActive, not recruiting
-
University of PennsylvaniaActive, not recruiting
-
Abramson Cancer Center at Penn MedicineActive, not recruitingProstate CancerUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI); Trevarx Biomedical, IncRecruitingBreast CarcinomaUnited States
-
University of PennsylvaniaRecruitingBreast CancerUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingRecurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Breast Carcinoma | Fallopian Tube Carcinoma | Ovarian Carcinoma | Primary Peritoneal Carcinoma | Solid NeoplasmUnited States